pgi

6-Phosphogluconic acid 是竞争性的磷酸葡萄糖异构酶抑制剂，对6-磷酸果糖和6-磷酸葡萄糖和的 Ki 分别为 42 μM 和 48 μM。它属于人内源性代谢物。

ELAAWCRWGFLLALLPPGIAG (P5) 是源自大鼠HER2 neu蛋白的21个氨基酸长肽（氨基酸5-25）。此肽可诱导携带HER2阳性肿瘤小鼠中的细胞毒性T淋巴细胞（CTL）反应。

ELAAWCRWGFLLALLPPGIAG TFA (P5) 是由大鼠HER2 neu蛋白衍生的21个氨基酸长的肽段（氨基酸序号5至25）。该化合物在携带HER2阳性肿瘤的小鼠模型中，能够诱发细胞毒性T淋巴细胞(CTL)的反应。

Eicosapentaenoic Acid 是一种 ω-3 脂肪酸。

U-51605, a stable analog of the endoperoxide prostaglandin H2 (PGH2), functions as an inhibitor with greater selectivity towards prostacyclin (PGI) synthase over thromboxane (TX) synthase. It also acts as a partial agonist at TP receptors. Studies show that at a concentration of 2.8 µM, U-51605 effectively inhibits PGI synthase in human foreskin fibroblasts, while a concentration of 5.6 µM is required to inhibit human platelet TX synthase. Furthermore, U-51605, at up to 1 µM, decreases the release of prostacyclin in SHR aorta triggered by the calcium ionophore A-23187 without impacting TXA2 production, and notably enhances the release of PGE2 and PGF2α.

PGI3 is synthesized from EPA by COX and PGI synthase. PGI3 has a short in vivo half-life and is hydrolyzed to δ17-6-keto PGF1α. The platelet and vascular activity of PGI3 is equivalent to that of PGI2.

Glucose 6-phosphate isomeras (GPI) 葡萄糖 6-磷酸异构酶，即磷酸葡萄糖异构酶 磷酸葡萄糖异构酶 (PGI) 或磷酸己糖异构酶 (PHI)，常用于生化研究。Glucose 6-phosphate isomeras 是一种高度保守的糖酵解酶和二聚酶。Glucose 6-phosphate isomeras 催化葡萄糖-6-磷酸异构成果糖-6-磷酸。

Anticanceragent 139（Compound 6h）展现了针对多种癌细胞株的抗癌效能。该化合物能够与Tubulin的Lys352残基发生π-阳离子相互作用。在对SNB-19、OVCAR-8和NCI-H460细胞株的测试中，Anticanceragent 139展现出较高的生长抑制率（PGI），数值分别为86.61、85.26和75.99。同时，该化合物对于HOP-62、SNB-75、ACHN、NCI ADR-RES、786-O、A549 ATCC、HCT-116以及MDA-MB-231细胞株亦表现出中等的生长抑制作用，其PGI值分别为67.55、65.46、59.09、59.02、57.88、56.88、56.53和56.4、51.88。